Abstract
Systemic lupus erythematosus (SLE) is increasingly recognized as a risk factor for the development of premature atherosclerosis. The inflammatory process in both of these diseases is controlled by a variety of cell types of the innate and adaptive immune systems. Recent studies from several groups, including ours, have revealed a critical role of a unique subset of lymphocytes, termed invariant natural killer T (iNKT) cells, in the development of lupus-like autoimmunity and atheroslerosis in animal models. iNKT cells appear to play complex and divergent roles in the development of SLE and atherosclerosis. Our findings suggest that alterations in iNKT cell functions during the development of SLE may be related to the increased risk of SLE patients to develop atherosclerosis and coronary heart disease. We found that iNKT cell activation with the sponge-derived glycolipid α-galactosylceramide generally protects against the development of lupus-like autoimmunity in nice, whereas it exacerbates atherosclerosis. Therefore, while our studies have identified iNKT cells as potential therapeutic targets for SLE, further studies are necessary to design drugs that will avoid the underlying harmful effects of iNKT cell activation on the development of atherosclerosis.
Similar content being viewed by others
References
Binder CJ, Chang MK, Shaw PX, et al.: Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218–1226.
Wick G, Knoflach M, Xu Q: Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004; 22: 361–403.
Lockshin MD, Salmon JE, Roman MJ: Atherosclerosis and lupus: a work in progress. Arthritis Rheum 2001; 44: 2215–2217.
Bendelac A, Rivera MN, Park SH, Roark JH: Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997; 15: 535–562.
Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H: The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003; 21: 483–531.
Van Kaer L: Regulation of immune responses by CD1d-restricted natural killer T cells. Immunol Res 2004; 30: 139–153.
Brigl M, Brenner MB: CD1: antigen presentation and T cell function. Annu Rev Immunol 2004; 22: 817–890.
Godfrey DI, Kronenberg M: Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004; 114: 1379–1388.
Kronenberg M: Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005; 26: 877–900.
Bezbradica JS, Joyce S: Natural T lymphocytes and dendritic cells: an innate duet that arouses and tempers immune responses; in Gorczynski RM (ed): Altered Immunoregulation, and Human Disease, Trivandrum, Kerala, India. Research Signpost 2005, pp. 137–163.
Kawano T, Cui J, Koezuka Y, et al.: CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997; 278: 1626–1629.
Gumperz JE, Roy C, Makowska A, et al.: Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 2000; 12: 211–221.
Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB: Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 2003;198:173–181.
Fischer K, Scotet E, Niemeyer M, et al: Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc Natl Acad Sci USA 2004; 101:10685–10690.
Amprey JL, Im JS, Turco SJ, et al: A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J Exp Med 2004; 200:895–904.
Stanic AK, De silva AD, Park JJ, et al: Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by β-D-glucosylceramide synthase deficiency. Proc Natl Acad Sci USA 2003;100:1849–1854.
Zhou D, Mattner J, Cantu C, et al: Lysosomal glycophin-golipid recognition by NKT cells. Science 2004;306:1786–1789.
Mattner J, DeBord KL, Ismail N, et al: Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005;434:525–529.
Kinjo Y, Wu DY, Kim G, et al: Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005;434:520–525.
Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR: Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligand for NKT cells. Eur J Immunol 2005;35:1692–1701.
Van Kaer L, Joyce S: Innate immunity: NKT cells in the spotlight. Curr Biol 2005;15:R429-R431.
Joyce S, Woods AS, Yewdell JW, et al: Natural ligand of mouse CD1d1; cellular glycosylphosphatidylinositol. Science 1998;279:1541–1544.
Park J-J, Kang SJ, De Silva AD, et al: Lipid-protein interactions: biosynthetic assembly of CD1 with lipids in the endoplasmic reticulum is evolutionarily conserved. Proc Natl Acad Sci USA 2004;101:1022–1026.
De Silva AD, Park JJ, Matsuki N, et al: Lipid protein interactions: the assembly of CD1d1 with cellular phospholipids occurs in the endoplasmic reticulum. J Immunol 2002;168:723–733.
Brozovic S, Nagaishi T, Yoshida M, et al: CD1d function is regulated by microsomal triglyceride transfer protein. Nat Med 2004;10:535–539.
Dougan SK, Salas A, Rava P, et al: Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. J Exp Med 2005;202:529–539.
Kang SJ, Cresswell P: Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells. Nat Immunol 2004;5:175–181.
Zhou D, Cantu Cr, Sagiv Y, et al: Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 2004;303:523–527.
van den Elzen P, Garg S, Leon L, et al: Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 2005;437:906–910.
Prigozy TI, Naidenko O, Qasba P, et al: Glycolipid antigen processing for presentation by CD1d molecules. Science 2001;291:664–667.
Kobayashi E., Motoki K, Uchida T, Fukushima H, Koezuka Y: KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995;7:529–534.
Bezbradica JS, Stanic AK, Matsuki N, et al: Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol 2005;174:4694–4705.
Schmieg J, Yang G, Franck RW, Van Rooijen N, Tsuji M: Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc Natl Acad Sci USA 2005;102:1127–1132.
Eberl G, MacDonald HR: Rapid death and regeneration of NKT cells in anti-CD3epsilon- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity 1998;9:345–353.
Eberl G, MacDonald HR: Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 2000;30:985–992.
Leite-de-Moraes MC, Herbelin A, Gouarin C, Koezuka Y, Schneider E, Dy M: Fas/Fas ligand interactions promote activation-induced cell death of NK T lymphocytes. J Immunol 2000;165:4367–4371.
Wilson MT, Johansson C, Olivares-Villagomez D, et al: The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 2003; 100:10913–10918.
Parekh VV, Singh AK, Wilson MT, et al: Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J Immunol 2004;173:3693–3706.
Singh N, Hong S, Scherer DC, et al: Cutting edge: Activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol 1999;163:2373–2377.
Fujii S, Shimizu K, Kronenberg M, Steinman RM: Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide-loaded DCs. Nat Immunol 2002;3: 867–874.
Matsuda JL, Gapin L, Baron JL, et al: Mouse Vα14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci USA 2003;100:8395–8400.
Parekh VV, Wilson MT, Olivares-Villagomez D, et al: Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005;115:2572–2583.
Crowe NY, Uldrich AP, Kyparissoudis K, et al: Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells. J Immunol 2003;171:4020–4027.
Harada M, Seino KI, Wakao H, et al: Down-regulation of the invariant Vα14 antigen receptor in NKT cells upon activation. Int Immunol 2004;16:241–247.
Ulrich AP, Crowe NY, Kyparissoudis K, et al: NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 2005;175:3092–3101.
Hong S, Wilson MT, Serizawa I, et al: The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7:1052–1056.
Singh AK, Wilson MT, Hong S, et al: Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001;194:1801–1811.
Singh AK, Yang J-Q, Parekh VV, et al: The natural killer T cell ligand α-galactosylceramide prevents or promotes pristance-induced lupus in mice. Eur J Immunol 2005;35:1143–1154.
Hayakawa Y, Berzins SP, Crowe NY, Godfrey DI, Smyth MJ: Antigen-induced tolerance by intrathymic modulation of self-recognizing inhibitory receptors. Nat Immunol 2004;5:590–596.
Van Kaer L: α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 2005;5:31–42.
Cui J, Watanabe N, Kawano T, et al: Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα14 natural killer T cells. J Exp Med 1999;190:783–792.
Liu R, La Cava A, Bai X-F, et al: Cooperation of iNKT cells and CD4+CD25+ Treg cells in the prevention of autoimmune myasthenia. J Immunol 2005;175:7898–7904.
Mars LT, Novak J, Liblau RS, Lehuen A: Therapeutic manipulation of iNKT cells in autoimmunity: modes of action and potential risks. Trends Immunol 2004;25:471–476.
Parekh VV, Wilson MT, Van Kaer L: INKT-cell responses to glycolipids. Crit Rev Immunol 2005;25:183–213.
Kotzin BL: Systemic lupus erythematosus. Cell 1996; 85:303–306.
Singh RR: SLE: translating lessons from model systems to human disease. Trends Immunol 2005;26:572–579.
Takeda k, Dennert G: The development of autoimmunity in C57BL/61pr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med 1993;177:155–164.
Mieza MA, Itoh T, Cui JQ, et al: Selective reduction of Vα14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol 1996;156:4035–4040.
Oishi Y, Sumida T, Sakamoto A, et al: Selective reduction and recovery of invariant Vα24JαQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus. J Rheumatol 2001;28:275–283.
van der Vliet HJ, von Blomberg BM, Nishi N, et al: Circulating Vα24+Vβ11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001;100:144–148.
Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T: Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune disease. Arthritis Rheum 2001;44:1127–1138.
Yang J-Q, Saxena V, Xu H, Van Kaer L, Wang CR, Singh RR: Repeated α-galactosylceramide administration results in expansion of Vα14 NKT cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol 2003;171:4439–4446.
Yang JQ, Chun T, Liu H, et al: CD1d deficiency exacer-bates inflammatory dermatitis in MRL-lpr/lpr mice. Eur J Immunol 2004;34:1723–1732.
Forestier C, Molano A, Im JS, et al: Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New Zealand White)F1 mice. J Immunol 2005;175:1763–770.
Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S: Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest 2003;112:1211–1222.
Yang JQ, Singh AK, Wilson MT, et al: Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J Immunol 2003;171:2142–2153.
Yoshimoto T, Bendelac A, Hu-Li J, Paul WE: Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4. Proc Natl Acad Sci USA 1995;92:11931–11934.
Garner B, Priestman DA, Stocker R, Harvey DJ, Butters TD, Platt FM: Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice. J Lipid Res 2002;43:205–214.
Mukhin DN, Chao FF, Kruth HS: Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis. Arterioscl Thromb Vasc Biol 1995;15:1607–1615.
Melian A, Geng YJ, Sukhova GK, Libby P, Porcelli S: CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am J Pathol 1999;155:775–786.
Chan WL, Pejnovic N, Hamilton H, et al: Atherosclerotic abdominal aortic aneurysm and the interaction between autologous human plaque-derived vascular smooth muscle cells, type 1 NKT, and helper T cells. Circ Res 2005;96:675–683.
Bobryshev YV, Lord RS: Expression of heat shock protein-70 by dendritic cells in the arterial intima and its potential significance in atherogenesis. J Vasc Surg 2002;35:368–375.
Breslow JL: Mouse models of atherosclerosis. Science 1996;272:685–688.
Major AS, Wilson MT, McCaleb JL, et al: Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004;24:2351–2357.
Nakai Y, Iwabuchi K, Fujii S, et al: Natural killer T cells accelerate atherogenesis in mice. Blood 2004;104: 2051–2059.
Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB: Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003;4:1230–1237.
Ostos MA, Recalde D, Zakin MM, Scott-Algara D: Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett 2002;519:23–29.
Major AS, Van Kaer L: The role of natural killer T cells in atherosclerosis. Curr Immunol Rev 2005;1:261–274.
Tupin E, Nicoletti A, Elhage R, et al: CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 2004;199:417–422.
Aslanian AM, Chapman HA, Charo IF: Transient role for CD1d-restricted natural killer T cells in the formation of atherosclerotic lesions. Arterioscl Thromb Vasc Biol 2005;25:628–632.
King VL, Szilvassy SJ, Daugherty A: Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor−/− mice. Arterioscler Thromb Vasc Biol 2002;22:456–461.
Davenport P, Tipping PG: The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163:1117–1125.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Major, A.S., Singh, R.R., Joyce, S. et al. The role of invariant natural killer T cells in lupus and atherogenesis. Immunol Res 34, 49–66 (2006). https://doi.org/10.1385/IR:34:1:49
Issue Date:
DOI: https://doi.org/10.1385/IR:34:1:49